Tema Cardiovascular and Metabolic ETF company info

What does Tema Cardiovascular and Metabolic ETF do?
Tema Obesity & Cardiometabolic ETF (NASDAQ:HRTS) is an exchange-traded fund (ETF) that invests in companies focused on developing solutions for obesity and cardiometabolic diseases. Launched in November 2023, HRTS tracks firms involved in weight-loss drugs, diabetes treatments, and other related areas. The fund offers exposure to this growing market with a relatively low expense ratio of 0.75%. It started trading around $26 per share and currently sits at $32, with over $61 million in assets under management.
Tema Cardiovascular and Metabolic ETF company media
Company Snapshot

Is Tema Cardiovascular and Metabolic ETF a public or private company?

key
Ownership
Public

How many people does Tema Cardiovascular and Metabolic ETF employ?

people
Employees
18

What sector is Tema Cardiovascular and Metabolic ETF in?

pie chart
Sector
ETF

Where is the head office for Tema Cardiovascular and Metabolic ETF?

location pin
Head Office
New York, United States

What year was Tema Cardiovascular and Metabolic ETF founded?

founded flag
Year Founded
2023
What does Tema Cardiovascular and Metabolic ETF specialise in?
/Investment Services /Equity Funds /Sector ETF /Cardiovascular Research /Metabolic Disorders /Financial Management

What are the products and/or services of Tema Cardiovascular and Metabolic ETF?

Overview of Tema Cardiovascular and Metabolic ETF offerings
Investing in companies pioneering cardiovascular treatments.
Funding metabolic disorder research initiatives.
Supporting technologies for non-invasive cardiovascular diagnostics.
Promoting advanced therapies for heart failure management.
Backing innovations in lipid management solutions.
Endorsing new approaches to obesity treatment development.